These results demonstrate that anti-β2-M Ab is an effective agent for prostate cancer treatment, and combination treatment with anti-β2-M Ab and radiation is significantly more effective than antibody only or radiation only treatment. The gene discussed is B2M; the disease is prostate carcinoma.